Burjeel Holdings, a leading super-specialty healthcare provider in the Middle East, has announced a record-breaking third quarter for 2025, with revenue soaring to Dh1.42 billion and net profit increasing by 27.5% year-on-year to Dh175 million. The Abu Dhabi-listed healthcare group attributed this exceptional performance to a combination of rising patient volumes, a richer case mix, and enhanced operational efficiencies across its expanding network in the UAE and Saudi Arabia. EBITDA for the quarter rose by 17.1% to Dh320 million, with margins improving to 22.5%, reflecting disciplined cost control and heightened demand for complex care services.
CEO John Sunil highlighted the results as a testament to Burjeel’s strategic investments and growing reputation in high-acuity care. ‘Our network’s strength and market positioning have enabled us to deliver clinical excellence and robust financial momentum,’ he stated. ‘We are now firmly established as the region’s foremost destination for advanced specialties, including oncology, organ transplantation, and precision medicine.’
Patient footfall reached 5.1 million in the first nine months of 2025, marking a 7.3% year-on-year increase. Inpatient volumes rose by 8.4% in Q3, driven by strong demand in oncology, cardiology, gastroenterology, and orthopedics. The group performed over 67,000 surgeries during this period, a 10.3% increase, with bed occupancy averaging 67%. Outpatient visits also grew, rising by 4.5% in Q3 and 7.2% year-to-date, supported by new day care and physiotherapy centers.
Burjeel Medical City (BMC), the group’s flagship tertiary care hub, posted standout results with Q3 EBITDA soaring 46.8% and margins hitting an all-time high of 22%. BMC’s revenue rose by 10.9% in the first nine months, fueled by rising oncology volumes and expanded specialty services. The group also achieved several medical milestones during the quarter, including the UAE’s youngest-ever liver transplant and the GCC’s first Hepatic Artery Infusion Pump procedure, further cementing its leadership in complex and precision care.
Despite temporary restrictions on certain insurance plans, Burjeel maintained momentum through increased inflows from premium insurers and self-paying patients. This shift, combined with a rise in complex procedures, helped offset volume moderation in the basic segment. The medical centers segment also showed strong growth, with revenue up 15.8% in Q3, reflecting the ramp-up of over 40 new facilities across the UAE and KSA.
Burjeel’s balance sheet remains robust, with net debt to EBITDA at 1.9x, and recent strategic investments—including the Dh186 million acquisition of a Dubai hospital building—expected to enhance long-term asset value. Looking ahead, the group plans to continue expanding its footprint and capabilities, supported by favorable market dynamics and a robust pipeline of projects. ‘Our exceptional teams remain the driving force behind our success,’ Sunil added, ‘ensuring every patient receives world-class care.’